News

With this acquisition, Shire plans to expand Advanced BioHealing’s manufacturing facility and research laboratories. Shire will add Dermagraft in its product portfolio, which is indicated for the use

The Swissmedic approval was based on the results from a Phase II study (Study 211) of Halaven and the Phase III EMBRACE study (Eisai Metastatic Breast Cancer Study

China BCT’s net income was $6.25m, or $0.16 per diluted share, compared to net income of $4.24m, or $0.00 per diluted share, for the comparable period last year.

Under the terms of the companies’ 2009 joint venture arrangement, Maxygen transferred all of its protein pharmaceutical programs and related assets and research and development personnel to Perseid

The ACR hybrid score combines conventional ACR20/50/70 scores with the mean percent change in all 7 ACR core components, providing a percent improvement from baseline on a continuous

IL-3 inhibitor is developed by the Molecular Immunology research group led by Matthias Mack at the University of Regensburg. IL-3 is a growth factor produced by activated T

Under the acquisition, Merck‘s wholly subsidiary Monarch Transaction has merged with and into Inspire by making Inspire a wholly subsidiary of Merck. Merck Neuroscience and Ophthalmology senior vice

The lawsuit alleged that Eli Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide. The agreement was originally

China Shenghuo’s net income was $85,701, or $0.01 per diluted share, compared to net income of $13,825, or $0.00 per diluted share, for the comparable period last year.